The clinical efficacy of therapeutic monoclonal antibodies for breast and colorectal cancer has allowed for more personalized treatments. However, resistances remain something to consider, as they do occur. Biomarkers of drug response can help us understand the underlying molecular mechanisms and promote the development of enhanced therapies. In this context, the ResMarkerDB web interface aims to facilitate the exploration of our current knowledge. It was developed to improve efforts for translational research to improve the identification of new and existing actionable biomarkers of pharmacological response in breast and colorectal cancer.
We recover this informative video (in Spanish) where Judith Pérez, a PhD student at GRIB – a mixed unit of the Hospital del Mar Medical Research Institute (IMIM) and the Department of Experimental and Health Sciences, Pompeu Fabra University (DCEXS-UPF) – explains in detail how biomarker-based cancer therapy works. The talk of the young researcher was framed within the first edition of the Biennal Ciutat i Ciència, an initiative that offered, throughout February 2019, more than 70 free scientific outreach Barcelona Biomedical Research Park (PRBB).
